Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report
Background: The response to first-line platinum doublets (cisplatin/etoposide) in small-cell lung cancer (SCLC) predicts the probability of subsequent response to second-line therapy. In general, the longer-lived the responses in first line, the better the outcome in second line, with the opposite p...
Gespeichert in:
| Veröffentlicht in: | Oncology research and treatment 2016-11, Vol.39 (11), p.720-723 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 723 |
|---|---|
| container_issue | 11 |
| container_start_page | 720 |
| container_title | Oncology research and treatment |
| container_volume | 39 |
| creator | Brzezniak, Christina Oronsky, Bryan Scicinski, Jan Caroen, Scott Cabrales, Pedro Dean Abrouk, Nacer Kim, Michelle M. Brown, James F. Reid, Tony R. Larson, Christopher Oronsky, Arnold Day, Regina Degesys, Aiste Carter, Corey A. |
| description | Background: The response to first-line platinum doublets (cisplatin/etoposide) in small-cell lung cancer (SCLC) predicts the probability of subsequent response to second-line therapy. In general, the longer-lived the responses in first line, the better the outcome in second line, with the opposite prognosis for shorter-lived responses. Resistant SCLC is defined as relapse within 90 days of platinum-doublet treatment, and predictably correlates with shortened survival compared with sensitive disease, defined as relapse after 90 days. Case Report: We present a patient with platinum-resistant SCLC that was rechallenged with cisplatin/etoposide in the context of the clinical trial TRIPLE THREAT (NCT02489903) after treatment with, and progression on, the resistance-reversing anticancer agent RRx-001. Conclusion: The prolonged partial response of this platinum-resistant SCLC to reintroduced carboplatin/etoposide after RRx-001 belies and contradicts the prevailing orthodoxy in oncology that rechallenge with chemotherapy after the emergence of resistance is an exercise in futility and risk, which potentially exposes patients to toxicity without benefit. |
| doi_str_mv | 10.1159/000449432 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1841795876</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1841795876</sourcerecordid><originalsourceid>FETCH-LOGICAL-c334t-41380b83889f4ddf5090183ca222adfaf06340ede760a6b67a803cde480cc00f3</originalsourceid><addsrcrecordid>eNpt0M1LwzAYBvAgiop68C4S8KKHar7apt5GmToYKHWeS9a-0eja1CT14-pfbsfmTp7evPDjycuD0DEll5TG2RUhRIhMcLaF9hnLkihmCdvevFOyh468fx0YZXEs02wX7bFUxjGXyT76yW37Ac4b22Kr8cNCBdP2TTQOtrPe1BAV4I0Pqg04WPwIrTfBfAB-zKc5VjqAwzMHKjQwiE8TXnB4ATzuTDRpmr61w-ZUB30wFS6Kr2g44xqPcK484AI668Ih2tFq4eFoPQ_Q0814lt9F0_vbST6aRhXnIkSCcknmkkuZaVHXOiYZoZJXijGmaq00SbggUEOaEJXMk1RJwqsahCRVRYjmB-h8lds5-96DD2VjfAWLhWrB9r6kUtA0GxpKBnqxopWz3jvQZedMo9x3SUm5bL3ctD7Y03VsP2-g3si_jgdwtgJvyj2D24D7YraKKLt6ed3Jv2r9yy-G-5FR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1841795876</pqid></control><display><type>article</type><title>Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report</title><source>MEDLINE</source><source>Karger Journals</source><source>Alma/SFX Local Collection</source><creator>Brzezniak, Christina ; Oronsky, Bryan ; Scicinski, Jan ; Caroen, Scott ; Cabrales, Pedro ; Dean Abrouk, Nacer ; Kim, Michelle M. ; Brown, James F. ; Reid, Tony R. ; Larson, Christopher ; Oronsky, Arnold ; Day, Regina ; Degesys, Aiste ; Carter, Corey A.</creator><creatorcontrib>Brzezniak, Christina ; Oronsky, Bryan ; Scicinski, Jan ; Caroen, Scott ; Cabrales, Pedro ; Dean Abrouk, Nacer ; Kim, Michelle M. ; Brown, James F. ; Reid, Tony R. ; Larson, Christopher ; Oronsky, Arnold ; Day, Regina ; Degesys, Aiste ; Carter, Corey A.</creatorcontrib><description>Background: The response to first-line platinum doublets (cisplatin/etoposide) in small-cell lung cancer (SCLC) predicts the probability of subsequent response to second-line therapy. In general, the longer-lived the responses in first line, the better the outcome in second line, with the opposite prognosis for shorter-lived responses. Resistant SCLC is defined as relapse within 90 days of platinum-doublet treatment, and predictably correlates with shortened survival compared with sensitive disease, defined as relapse after 90 days. Case Report: We present a patient with platinum-resistant SCLC that was rechallenged with cisplatin/etoposide in the context of the clinical trial TRIPLE THREAT (NCT02489903) after treatment with, and progression on, the resistance-reversing anticancer agent RRx-001. Conclusion: The prolonged partial response of this platinum-resistant SCLC to reintroduced carboplatin/etoposide after RRx-001 belies and contradicts the prevailing orthodoxy in oncology that rechallenge with chemotherapy after the emergence of resistance is an exercise in futility and risk, which potentially exposes patients to toxicity without benefit.</description><identifier>ISSN: 2296-5270</identifier><identifier>EISSN: 2296-5262</identifier><identifier>DOI: 10.1159/000449432</identifier><identifier>PMID: 27855386</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Azetidines - administration & dosage ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Cisplatin - administration & dosage ; Drug Administration Schedule ; Drug Resistance, Neoplasm - drug effects ; Etoposide - administration & dosage ; Humans ; Lung Neoplasms - drug therapy ; Male ; Middle Aged ; Nitro Compounds - administration & dosage ; Novel Insights from Clinical Practice ; Treatment Outcome</subject><ispartof>Oncology research and treatment, 2016-11, Vol.39 (11), p.720-723</ispartof><rights>2016 S. Karger GmbH, Freiburg</rights><rights>2016 S. Karger GmbH, Freiburg.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c334t-41380b83889f4ddf5090183ca222adfaf06340ede760a6b67a803cde480cc00f3</citedby><cites>FETCH-LOGICAL-c334t-41380b83889f4ddf5090183ca222adfaf06340ede760a6b67a803cde480cc00f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2427,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27855386$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brzezniak, Christina</creatorcontrib><creatorcontrib>Oronsky, Bryan</creatorcontrib><creatorcontrib>Scicinski, Jan</creatorcontrib><creatorcontrib>Caroen, Scott</creatorcontrib><creatorcontrib>Cabrales, Pedro</creatorcontrib><creatorcontrib>Dean Abrouk, Nacer</creatorcontrib><creatorcontrib>Kim, Michelle M.</creatorcontrib><creatorcontrib>Brown, James F.</creatorcontrib><creatorcontrib>Reid, Tony R.</creatorcontrib><creatorcontrib>Larson, Christopher</creatorcontrib><creatorcontrib>Oronsky, Arnold</creatorcontrib><creatorcontrib>Day, Regina</creatorcontrib><creatorcontrib>Degesys, Aiste</creatorcontrib><creatorcontrib>Carter, Corey A.</creatorcontrib><title>Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report</title><title>Oncology research and treatment</title><addtitle>Oncol Res Treat</addtitle><description>Background: The response to first-line platinum doublets (cisplatin/etoposide) in small-cell lung cancer (SCLC) predicts the probability of subsequent response to second-line therapy. In general, the longer-lived the responses in first line, the better the outcome in second line, with the opposite prognosis for shorter-lived responses. Resistant SCLC is defined as relapse within 90 days of platinum-doublet treatment, and predictably correlates with shortened survival compared with sensitive disease, defined as relapse after 90 days. Case Report: We present a patient with platinum-resistant SCLC that was rechallenged with cisplatin/etoposide in the context of the clinical trial TRIPLE THREAT (NCT02489903) after treatment with, and progression on, the resistance-reversing anticancer agent RRx-001. Conclusion: The prolonged partial response of this platinum-resistant SCLC to reintroduced carboplatin/etoposide after RRx-001 belies and contradicts the prevailing orthodoxy in oncology that rechallenge with chemotherapy after the emergence of resistance is an exercise in futility and risk, which potentially exposes patients to toxicity without benefit.</description><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Azetidines - administration & dosage</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Drug Administration Schedule</subject><subject>Drug Resistance, Neoplasm - drug effects</subject><subject>Etoposide - administration & dosage</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nitro Compounds - administration & dosage</subject><subject>Novel Insights from Clinical Practice</subject><subject>Treatment Outcome</subject><issn>2296-5270</issn><issn>2296-5262</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0M1LwzAYBvAgiop68C4S8KKHar7apt5GmToYKHWeS9a-0eja1CT14-pfbsfmTp7evPDjycuD0DEll5TG2RUhRIhMcLaF9hnLkihmCdvevFOyh468fx0YZXEs02wX7bFUxjGXyT76yW37Ac4b22Kr8cNCBdP2TTQOtrPe1BAV4I0Pqg04WPwIrTfBfAB-zKc5VjqAwzMHKjQwiE8TXnB4ATzuTDRpmr61w-ZUB30wFS6Kr2g44xqPcK484AI668Ih2tFq4eFoPQ_Q0814lt9F0_vbST6aRhXnIkSCcknmkkuZaVHXOiYZoZJXijGmaq00SbggUEOaEJXMk1RJwqsahCRVRYjmB-h8lds5-96DD2VjfAWLhWrB9r6kUtA0GxpKBnqxopWz3jvQZedMo9x3SUm5bL3ctD7Y03VsP2-g3si_jgdwtgJvyj2D24D7YraKKLt6ed3Jv2r9yy-G-5FR</recordid><startdate>20161101</startdate><enddate>20161101</enddate><creator>Brzezniak, Christina</creator><creator>Oronsky, Bryan</creator><creator>Scicinski, Jan</creator><creator>Caroen, Scott</creator><creator>Cabrales, Pedro</creator><creator>Dean Abrouk, Nacer</creator><creator>Kim, Michelle M.</creator><creator>Brown, James F.</creator><creator>Reid, Tony R.</creator><creator>Larson, Christopher</creator><creator>Oronsky, Arnold</creator><creator>Day, Regina</creator><creator>Degesys, Aiste</creator><creator>Carter, Corey A.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20161101</creationdate><title>Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report</title><author>Brzezniak, Christina ; Oronsky, Bryan ; Scicinski, Jan ; Caroen, Scott ; Cabrales, Pedro ; Dean Abrouk, Nacer ; Kim, Michelle M. ; Brown, James F. ; Reid, Tony R. ; Larson, Christopher ; Oronsky, Arnold ; Day, Regina ; Degesys, Aiste ; Carter, Corey A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c334t-41380b83889f4ddf5090183ca222adfaf06340ede760a6b67a803cde480cc00f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Azetidines - administration & dosage</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Drug Administration Schedule</topic><topic>Drug Resistance, Neoplasm - drug effects</topic><topic>Etoposide - administration & dosage</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nitro Compounds - administration & dosage</topic><topic>Novel Insights from Clinical Practice</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brzezniak, Christina</creatorcontrib><creatorcontrib>Oronsky, Bryan</creatorcontrib><creatorcontrib>Scicinski, Jan</creatorcontrib><creatorcontrib>Caroen, Scott</creatorcontrib><creatorcontrib>Cabrales, Pedro</creatorcontrib><creatorcontrib>Dean Abrouk, Nacer</creatorcontrib><creatorcontrib>Kim, Michelle M.</creatorcontrib><creatorcontrib>Brown, James F.</creatorcontrib><creatorcontrib>Reid, Tony R.</creatorcontrib><creatorcontrib>Larson, Christopher</creatorcontrib><creatorcontrib>Oronsky, Arnold</creatorcontrib><creatorcontrib>Day, Regina</creatorcontrib><creatorcontrib>Degesys, Aiste</creatorcontrib><creatorcontrib>Carter, Corey A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Oncology research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brzezniak, Christina</au><au>Oronsky, Bryan</au><au>Scicinski, Jan</au><au>Caroen, Scott</au><au>Cabrales, Pedro</au><au>Dean Abrouk, Nacer</au><au>Kim, Michelle M.</au><au>Brown, James F.</au><au>Reid, Tony R.</au><au>Larson, Christopher</au><au>Oronsky, Arnold</au><au>Day, Regina</au><au>Degesys, Aiste</au><au>Carter, Corey A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report</atitle><jtitle>Oncology research and treatment</jtitle><addtitle>Oncol Res Treat</addtitle><date>2016-11-01</date><risdate>2016</risdate><volume>39</volume><issue>11</issue><spage>720</spage><epage>723</epage><pages>720-723</pages><issn>2296-5270</issn><eissn>2296-5262</eissn><abstract>Background: The response to first-line platinum doublets (cisplatin/etoposide) in small-cell lung cancer (SCLC) predicts the probability of subsequent response to second-line therapy. In general, the longer-lived the responses in first line, the better the outcome in second line, with the opposite prognosis for shorter-lived responses. Resistant SCLC is defined as relapse within 90 days of platinum-doublet treatment, and predictably correlates with shortened survival compared with sensitive disease, defined as relapse after 90 days. Case Report: We present a patient with platinum-resistant SCLC that was rechallenged with cisplatin/etoposide in the context of the clinical trial TRIPLE THREAT (NCT02489903) after treatment with, and progression on, the resistance-reversing anticancer agent RRx-001. Conclusion: The prolonged partial response of this platinum-resistant SCLC to reintroduced carboplatin/etoposide after RRx-001 belies and contradicts the prevailing orthodoxy in oncology that rechallenge with chemotherapy after the emergence of resistance is an exercise in futility and risk, which potentially exposes patients to toxicity without benefit.</abstract><cop>Basel, Switzerland</cop><pmid>27855386</pmid><doi>10.1159/000449432</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2296-5270 |
| ispartof | Oncology research and treatment, 2016-11, Vol.39 (11), p.720-723 |
| issn | 2296-5270 2296-5262 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1841795876 |
| source | MEDLINE; Karger Journals; Alma/SFX Local Collection |
| subjects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage Azetidines - administration & dosage Carcinoma, Non-Small-Cell Lung - drug therapy Cisplatin - administration & dosage Drug Administration Schedule Drug Resistance, Neoplasm - drug effects Etoposide - administration & dosage Humans Lung Neoplasms - drug therapy Male Middle Aged Nitro Compounds - administration & dosage Novel Insights from Clinical Practice Treatment Outcome |
| title | Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T02%3A38%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Conversion%20of%20Platinum-Etoposide-Resistant%20to%20Sensitive%20SCLC%20after%20Treatment%20with%20the%20Epi-Immunotherapeutic%20RRx-001:%20A%20Case%20Report&rft.jtitle=Oncology%20research%20and%20treatment&rft.au=Brzezniak,%20Christina&rft.date=2016-11-01&rft.volume=39&rft.issue=11&rft.spage=720&rft.epage=723&rft.pages=720-723&rft.issn=2296-5270&rft.eissn=2296-5262&rft_id=info:doi/10.1159/000449432&rft_dat=%3Cproquest_cross%3E1841795876%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1841795876&rft_id=info:pmid/27855386&rfr_iscdi=true |